Core Viewpoint - Smoore International (06969) reported significant revenue growth in Q3 2025, reaching 4.197 billion yuan, a 27.2% year-on-year increase, but faced declining profitability with a net profit of 317 million yuan, down 16.4% year-on-year [1][11] Revenue Performance - The company achieved a record high quarterly revenue, with total revenue for the first three quarters of 2025 at 10.21 billion yuan, up 21.8% year-on-year [1] - Revenue growth was primarily driven by the enterprise client business and proprietary brand business, with overseas markets, particularly Europe and the US, contributing over 97% of revenue [1][5] Profitability Challenges - Despite revenue growth, net profit has declined for four consecutive years, with a net profit margin dropping to 7.92% in the first three quarters of 2025 [1][10] - The gross margin has also decreased from 43.3% in 2022 to 37.3% in the first half of 2025, indicating pressure on profitability [10] Business Segments - The company operates two main business segments: enterprise client business and proprietary brand business, both focusing on overseas markets, especially Europe [5][6] - The enterprise client business generated 2.734 billion yuan in Europe and other countries in the first half of 2025, a 38% increase, accounting for 57.7% of this segment's revenue [5] - The proprietary brand business saw revenue of 1.07 billion yuan in Europe and other countries, a 15.1% increase, contributing 84% of its segment revenue [5] Research and Development - Smoore International has invested heavily in R&D, with total R&D expenditure of 722 million yuan in the first half of 2025, focusing on electronic nicotine delivery systems [7][9] - The company holds a significant number of patents, with 839 new patent applications globally, indicating a strong commitment to innovation [9] Market Outlook - The company has shifted its market strategy post-2022, focusing on overseas expansion to recover from previous declines in revenue [2][11] - Despite challenges in the US and China markets, the company anticipates continued high growth in Europe and other international markets [6][11] Investment Sentiment - Analysts have mixed views on Smoore International, with some predicting revenue growth driven by electronic cigarette sales but cautioning about rising costs and declining net profit [11] - Others remain optimistic about the company's potential for recovery and growth, particularly in the HNB product line [11]

Core Viewpoint - Guojin Securities maintains a "Buy" rating for Smoore International (06969), projecting EPS for 2025-2027 to be 0.22, 0.39, and 0.59 yuan respectively, with corresponding PE ratios of 67, 37, and 25 times at the current stock price [1] Financial Performance Summary - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit and adjusted net profit (excluding stock incentive expenses) at 809 million and 1.182 billion yuan, reflecting a year-on-year decrease of 23.8% and an increase of 0.1% respectively [1] - In Q3 2025, the company reported revenue of 4.197 billion yuan, a year-on-year increase of 27.2%, with net profit and adjusted net profit at 317 million and 444 million yuan, showing a year-on-year decrease of 16.4% and an increase of 4.0% respectively [1][2] Business Segment Insights - The HNB (Heated Not Burn) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth, alongside increasing regulatory scrutiny on illegal products in Europe and the US [1] - The vaping business is anticipated to achieve double-digit growth in Q3 2025, benefiting from market shifts in Europe and increased enforcement against illegal products in the US [1] - The company is focusing on the iteration and expansion of its own brand series, with a steady increase in market share, and expects favorable growth in its APV (Advanced Personal Vaporizer) business [1][2] Profitability Outlook - Adjusted net profit for Q3 2025 increased by 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, down from 11.5% in Q3 2024 [2] - Despite a year-on-year decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated increase in profitability from HNB products as sales volume grows [2] - The company is also increasing R&D investments in medical nebulization, with recent FDA acceptance of a subsidiary's abbreviated new drug application indicating progress in this area [2] Market Expansion and Growth Potential - The expansion of the legal vaping market in Europe and the US is a prevailing trend, with the HNB product glo hilo starting promotions in Poland, indicating potential for global sales growth [2] - The company is positioned as a unique player deeply integrated into the supply chains of both vaping and HNB products, suggesting a clear path for future growth [2]

Core Viewpoint - Guojin Securities maintains a "Buy" rating for Smoore International (06969), projecting EPS for 2025-2027 to be 0.22, 0.39, and 0.59 yuan respectively, with current stock prices corresponding to PE ratios of 67, 37, and 25 times [1] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit and adjusted net profit (excluding stock incentive costs) at 808 million and 1.182 billion yuan, reflecting a year-on-year decrease of 23.8% and an increase of 0.1% respectively [1] - In Q3 2025, the company reported revenue of 4.197 billion yuan, a year-on-year increase of 27.2%, with net profit and adjusted net profit at 317 million and 444 million yuan, showing a year-on-year decrease of 16.4% and an increase of 4.0% respectively [1][2] Business Segments - The HNB (Heat-not-Burn) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth [1] - The vaping business is anticipated to achieve double-digit growth in Q3 2025, benefiting from regulatory changes in Europe and increased enforcement against illegal products in the U.S. [1] - The company is focusing on the iteration and expansion of its own brand series, with a steady increase in market share for its OBM (Own Brand Manufacturing) business [1] Profitability Outlook - The adjusted net profit for Q3 2025 increased by 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, slightly down from 11.5% in Q3 2024 [2] - Despite a decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated increase in HNB business profitability as sales volume grows [2] Market Expansion - The expansion of the legal vaping market in Europe and the U.S. is a significant trend, with the HNB product glo hilo starting promotions in Poland, indicating potential for global sales growth [3] - The company is positioned as a unique player deeply involved in the supply chains of both vaping and HNB products, suggesting a clear path for future growth [3]

Core Viewpoint - The company reported a significant revenue increase in Q3 2025, driven by the HNB and vaping business, despite a decline in net profit due to initial low-margin sales and ongoing investments in R&D [1][2] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit of 809 million yuan, down 23.8% [1] - In Q3 2025, revenue reached 4.197 billion yuan, up 27.2% year-on-year, while net profit was 317 million yuan, a decrease of 16.4% [1] Business Analysis - The HNB business is expected to contribute significantly to revenue, with the HNB product "hilo" launched in Japan and Poland, leading to strong sales [1] - The vaping business is projected to see double-digit growth in Q3 2025, benefiting from regulatory changes in Europe and increased enforcement against illegal products in the U.S. [1] - The company is focusing on brand development and market expansion, with a steady increase in market share for its own brands [1] - The adjusted net profit for Q3 2025 showed a year-on-year increase of 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6% [1] Growth Outlook - The expansion of the legal vaping market in Europe and the U.S. is expected to continue, with the HNB product "glo hilo" gaining traction in Poland [2] - The company is positioned uniquely in the market as a supplier in both vaping and HNB categories, indicating a strong growth potential [2] Earnings Forecast and Valuation - The company forecasts EPS of 0.22, 0.39, and 0.59 yuan for 2025-2027, with corresponding PE ratios of 67, 37, and 25 times [2]

Group 1 - The company reported Q3 2025 financial data, with revenue of 4.197 billion yuan, a year-on-year increase of 27.5%, and adjusted profit of 444 million yuan, a year-on-year increase of 4.8% [1] - HNB is expected to become a major growth driver, with significant revenue increase anticipated due to the pre-production nature and the full rollout of hilo in Japan, leading to substantial sequential growth in sales [1] - The ODM+ strategy has been further validated, with satisfactory growth from new product iterations, and overall growth expected to exceed double digits as new compliant products are launched [1] Group 2 - Emerging businesses are expected to elevate the company's valuation, with the subsidiary successfully submitting an ANDA for Breo Ellipta, which is used for asthma and COPD treatment, indicating potential for further valuation uplift [1] - The company anticipates that HNB will become a primary source of profit release by 2026, with traditional vaping business valuation solidifying [2] - Revenue projections for 2025-2027 are 14.2 billion, 16.9 billion, and 19.5 billion yuan, with corresponding net profits of 1.395 billion, 1.898 billion, and 2.368 billion yuan, leading to PE ratios of 64.53x, 47.44x, and 38.02x respectively, maintaining a "buy" rating [2]

Summary of Smoore International's Conference Call Company Overview - **Company**: Smoore International - **Industry**: Electronic smoking devices and related products Key Points and Arguments Financial Performance - **Q3 Revenue Growth**: Smoore International reported a 27.5% increase in revenue for Q3 2025, exceeding market expectations, with adjusted profit rising by 4.8% quarter-over-quarter [2][3] - **HNB Product Sales**: The strong performance was driven by robust sales of Heat-Not-Burn (HNB) products, with expectations of at least 1.2 billion RMB in annual revenue from HNB [3][4] - **Traditional Vaping Products**: The traditional vaping segment also saw significant growth, particularly in Europe, due to the introduction of new products following a ban on disposable e-cigarettes [2][3] Market Dynamics - **European Market**: The European market outperformed overall company growth, driven by regulatory changes and the introduction of new products [2][5] - **U.S. Market Recovery**: The U.S. market is recovering more slowly, but stricter regulations on compliant products are creating opportunities for Smoore's partners, such as British American Tobacco's VUSE brand [5] Strategic Initiatives - **Expansion of HNB Markets**: Smoore is entering more core markets for HNB products, including Poland and Italy, aiming to transition from the initial development phase to a more expansive growth phase [7] - **Collaboration with British American Tobacco**: The partnership with British American Tobacco is seen as a significant growth opportunity, enhancing Smoore's product offerings and market reach [4][10] Product Development - **Medical Nebulization**: Smoore is investing heavily in the medical nebulization sector, with expectations to generate revenue starting in 2026. The company has submitted multiple products for FDA approval [4][11] - **Free Brand WAPER**: The company is increasing market share for its free brand WAPER through enhanced channel coverage and localized operations, despite limited elasticity in this segment [6] Future Outlook - **Profitability Expectations**: While current profits are not exceptionally high, Smoore anticipates improved profitability from 2026 onwards, driven by regulatory changes and market share expansion [9] - **Valuation and Market Potential**: Following recent stock price adjustments, Smoore's valuation is seen as attractive, with a static P/E ratio of 58x for 2025, expected to drop to 39x in 2026 and 29x in 2027, indicating significant future earnings potential [12] Long-term Growth Areas - **Beauty Nebulization**: The beauty nebulization segment is part of Smoore's long-term strategy, expected to follow the medical nebulization developments, with promising growth potential [13] New Business Contributions - **Initial Profit Contributions**: New business segments are expected to have limited profit contributions initially, which is typical for early-stage promotions. The focus is on market share, with profitability expected to improve as sales volumes increase in subsequent years [14] Additional Important Insights - **Production Capacity**: Smoore has automated production capabilities for 2 million devices and plans to increase this to over 5 million, with monthly production of 2 million cartridges [10] - **Market Positioning**: Smoore positions itself as a technology platform, providing differentiated solutions to various tobacco companies, not just British American Tobacco [7][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a significant revenue and profit increase in Q3 2025, with revenue reaching 4.197 billion yuan, a year-on-year growth of 27.5%, and adjusted profit of 444 million yuan, up 4.8% year-on-year [7] - The HNB (Heat Not Burn) segment is expected to become a major growth driver, with substantial sales growth anticipated in Japan and Europe [7] - The ODM+ strategy has shown satisfactory growth due to successful product iterations, with overall growth expected to exceed double digits [7] - The valuation of the company is expected to rise with the introduction of new compliant products and the recent FDA acceptance of a generic drug application for Breo® Ellipta® [7] - The company forecasts revenues of 14.2 billion, 16.9 billion, and 19.5 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 1.395 billion, 1.898 billion, and 2.368 billion yuan [7] Financial Performance Summary - Revenue projections for the company are as follows: 11,168 million yuan in 2023, 11,799 million yuan in 2024, 14,200 million yuan in 2025, 16,900 million yuan in 2026, and 19,500 million yuan in 2027, with a revenue growth rate of 20.35% in 2025 [6][8] - The net profit forecast shows a decline in 2024 to 1,303 million yuan, followed by a recovery to 1,395 million yuan in 2025, and further growth to 1,898 million yuan in 2026 and 2,368 million yuan in 2027 [6][8] - The company's EPS is projected to be 0.23 yuan in 2025, 0.31 yuan in 2026, and 0.38 yuan in 2027, with corresponding PE ratios of 64.53x, 47.44x, and 38.02x [6][8]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4]. Core Insights - The company reported a revenue of 10.21 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 21.8%. However, net profit decreased by 23.8% to 809 million yuan, while adjusted net profit remained stable with a slight increase of 0.1% to 1.182 billion yuan [2][3]. - The HNB (Heated Not Burned) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth. The company anticipates double-digit growth in its vaping business, benefiting from regulatory changes in Europe and the U.S. [2][3]. - The adjusted net profit for Q3 2025 showed a year-on-year increase of 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, slightly down from 11.5% in Q3 2024. Despite the decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated growth in HNB product sales and ongoing investments in medical vaping [3]. Financial Summary - The company forecasts EPS (Earnings Per Share) of 0.22, 0.39, and 0.59 yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 67, 37, and 25 times [4]. - Revenue projections for 2025-2027 are 14.382 billion, 17.486 billion, and 20.589 billion yuan, with growth rates of 21.9%, 21.6%, and 17.7% respectively. Net profit is expected to recover, with growth rates of 3.0%, 78.1%, and 52.2% for the same period [9].

Core Insights - The report from CICC indicates that the consumption data for the National Day and Mid-Autumn Festival holidays in 2025 shows strong performance, driven by longer holiday periods and a high level of domestic and outbound travel [1] Group 1: Consumption Trends - Overall consumption data reflects a youthful and experience-oriented trend, with notable performance in discretionary categories such as home appliances and outdoor sports [1] - The average daily flow of cross-regional personnel in mainland China from October 1 to 8 increased by 6.2% year-on-year, indicating a robust travel environment [1] - The average spending per trip during the holiday increased by 14.6% year-on-year, attributed to the ongoing recovery of outbound tourism and a rise in long-distance and segmented travel within the country [1] Group 2: Retail Performance - The Ministry of Commerce's monitoring of 78 key business districts showed a year-on-year increase in foot traffic and sales of 4.2% and 4% respectively during the first three days of the holiday [1] - Data from the National Immigration Administration revealed that the average daily number of inbound and outbound travelers exceeded 2 million, marking a 15% year-on-year increase [1] Group 3: Investment Recommendations - CICC recommends focusing on sectors benefiting from self-indulgent consumption trends, such as trendy toys and e-cigarettes, highlighting companies like Pop Mart (09992), Blucor (00325), and Smoore International (06969) [1] - The report also suggests investing in domestic brands in the beauty and personal care sectors, recommending companies like Mao Geping (01318), Giant Bio (02367), and Shanghai Jahwa (600315) [1] - Attention is drawn to retail sectors that may benefit from supportive domestic policies and seasonal catalysts [1]

Core Viewpoint - Smoore International (06969.HK) experienced significant stock price volatility following the release of its Q3 2025 earnings report, which showed mixed results with high revenue growth but declining net profits [2][3]. Financial Performance - For Q3 2025, Smoore International reported revenue of approximately 4.197 billion RMB, marking a year-on-year increase of 27.2% and a quarter-on-quarter increase of 27.5% [3]. - The company's net profit for the same period was approximately 316.9 million RMB, reflecting a year-on-year decline of 16.4% but a quarter-on-quarter increase of 5.7% [3]. - Adjusted profit for Q3 was 444.2 million RMB, showing a year-on-year growth of 4.0% and a quarter-on-quarter growth of 4.8% [3]. Business Segments - Smoore International operates primarily in two business segments: 1. Business-to-Business (B2B) services, providing electronic vaporization devices and HNB (Heated Not Burn) solutions to global tobacco giants 2. Research, design, manufacturing, and sales of proprietary electronic vaporization products and vaporization beauty products [4]. Revenue Drivers - The revenue growth was attributed to the strong performance of the B2B segment and the proprietary brand business, with significant increases in product shipments and successful launches of new compliant electronic vaporization products [5]. - The proprietary brand business also saw healthy growth due to successful product iterations and increased marketing efforts tailored to local markets [5]. Profitability Challenges - Despite strong revenue growth, Smoore International faces significant pressure on profitability due to rising costs associated with global market expansion, compliance, R&D, and marketing [5]. - Analysts remain cautious about the company's future profit outlook, with expectations of a 40% decline in net profit year-on-year for 2025, despite a projected 20% revenue growth driven by electronic cigarette sales [6].